NCT03213509 is a clinical trial of Interview (Social and Verbal Autopsy) in Perinatal Death, sponsored by Harvard School of Public Health (HSPH).

Who is sponsoring NCT03213509?

NCT03213509 is sponsored by Harvard School of Public Health (HSPH).

What drugs are being tested in NCT03213509?

Interventions in NCT03213509: Interview (Social and Verbal Autopsy).

What condition does NCT03213509 study?

NCT03213509 studies Perinatal Death, Neonatal Death, Stillbirth.

Is NCT03213509 still recruiting?

NCT03213509 is currently completed. Last updated 17 October 2019.

Are results published for NCT03213509?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-10-17 · How we verify

NCT03213509

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Verbal Autopsy of Maternal Deaths, Stillbirths, and Neonatal Deaths in BetterBirth

Completed Results posted Last updated 17 October 2019

What this trial tests

trial testing Interview (Social and Verbal Autopsy) in Perinatal Death in 170 participants. Completed in 27 August 2017.

Timeline

3 July 2017

Primary endpoint
27 August 2017

27 August 2017

Quick facts

Lead sponsor	Harvard School of Public Health (HSPH)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	170
Start date	3 July 2017
Primary completion	27 August 2017
Estimated completion	27 August 2017
Sites	1 location across India

Drugs / interventions tested

Interview (Social and Verbal Autopsy)

Conditions studied

Perinatal Death — all drugs for Perinatal Death →
Neonatal Death — all drugs for Neonatal Death →
Stillbirth — all drugs for Stillbirth →

Sponsor

Harvard School of Public Health (HSPH)

Who can join

18 and older, any sex, with Perinatal Death or Neonatal Death. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Cause of Death Primary · Early post-natal period (up to 7 days post-partum)

Cause of perinatal mortality

Stillbirth

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	20
Perinatal Death With Pause Point(s) Observed, Control Arm	35

Early Neonatal Death

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	56
Perinatal Death With Pause Point(s) Observed, Control Arm	50

Cause of Stillbirth Primary · Early post-natal period (up to 7 days post-partum)

Cause of Stillbirth

Obstructed Labor

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	3
Perinatal Death With Pause Point(s) Observed, Control Arm	12

Other Specific Perinatal Cause

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	9
Perinatal Death With Pause Point(s) Observed, Control Arm	9

Other Obstetric Complication

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	2
Perinatal Death With Pause Point(s) Observed, Control Arm	4

Antepartum Hemorrhage

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	3
Perinatal Death With Pause Point(s) Observed, Control Arm	3

Other

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	2
Perinatal Death With Pause Point(s) Observed, Control Arm	3

Unknown

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	1
Perinatal Death With Pause Point(s) Observed, Control Arm	4

Cause of Early Neonatal Death Primary · Early post-natal period (up to 7 days post-partum)

Cause of Early Neonatal Death

Perinatal Asphyxia

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	26
Perinatal Death With Pause Point(s) Observed, Control Arm	26

Infection

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	13
Perinatal Death With Pause Point(s) Observed, Control Arm	9

Pre-Term Birth Complications

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	8
Perinatal Death With Pause Point(s) Observed, Control Arm	11

Other Specific Perinatal Cause

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	1
Perinatal Death With Pause Point(s) Observed, Control Arm	2

Congenital Malformations

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	3
Perinatal Death With Pause Point(s) Observed, Control Arm	0

Unknown

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	5
Perinatal Death With Pause Point(s) Observed, Control Arm	2

Sex of Babies Who Suffered Perinatal Mortality Secondary · Within 7 days postpartum

This measure refers to the sex of the babies who suffered a perinatal mortality, and whose mother/family member was interviewed about the death via verbal autopsy

Group	Value	95% CI
Perinatal Death With Pause Point(s) Observed, Intervention Arm	41
Perinatal Death With Pause Point(s) Observed, Control Arm	50
Perinatal Death With Pause Point(s) Observed, Intervention Arm	35
Perinatal Death With Pause Point(s) Observed, Control Arm	35

Sponsor's own description

The purpose of this study is to conduct Verbal Autopsies of deaths ( stillbirths and neonatal deaths together) identified in the BetterBirth trial to identify their potential causes, timing, and social determinants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Perinatal Death

Currently open trials in the same condition.

NCT05187897 — CHV-NEO: Community-based Digital Communication to Support Neonatal Health · NA · recruiting
NCT06005272 — Mothers Working to Prevent Early Stillbirth Study 20-28 · recruiting
NCT06125860 — BEP Targeting Strategies in Ethiopia · NA · recruiting
NCT06273007 — Improving Intrapartum Care for Saving Life at Birth in Ethiopia Through PartoMa Approach · NA · recruiting
NCT04766866 — sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term. · NA · recruiting

Other Harvard School of Public Health (HSPH) trials

Trials by the same sponsor.

NCT07493772 — Multiple Micronutrient Supplementation With Digital Layering Among Adolescents in Tanzania · NA · not yet recruiting
NCT06982339 — Beat the Heat Boston · NA · recruiting
NCT06765863 — LIFT-UP: Randomized Controlled Trial of Fortification of Human Milk · NA · recruiting
NCT06102044 — Zinc Supplementation for Young Infants With Clinical Severe Infection in Tanzania · Phase 3 · recruiting
NCT06390943 — Low Birthweight and Preterm Infant Feeding Trial and Supportive Care Package: Implementation Research · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03213509 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Harvard School of Public Health (HSPH)
Last refreshed: 17 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03213509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing